A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)

NCT00389740 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: MK0217, /Duration of Treatment : 12 Months
DRUG: Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months

Sponsor

Organon and Co